Mutant tetraprenyl-β-curcumen cyclase and method for producing ambrein using the same
A mutant tetraprenyl-β-curcumene cyclase with specific mutations efficiently converts squalene into ambraine, addressing inefficiencies in existing production methods by enhancing enzyme activity and yield at elevated temperatures.
Patent Information
- Application Number
- JP2023072476
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-26
- Publication Date
- 2024-11-08
AI Technical Summary
Existing methods for producing ambraine, a key component of ambergris, are inefficient and do not allow for its easy and large-scale production.
A mutant tetraprenyl-β-curcumene cyclase with specific amino acid mutations, such as D373C, is used to convert squalene into 8α-hydroxypolypoda-13,17,21-triene and ambraine in high yield, enhancing enzyme activity and thermostability.
The mutant cyclase efficiently produces bicyclic triterpenes like 8α-hydroxypolypoda-13,17,21-triene and ambraine at higher temperatures, improving yield and enzyme activity, particularly at 37°C, the average E. coli culture temperature.
Smart Images

Figure 2024157855000001 
Figure 2024157855000002 
Figure 2024157855000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a mutant tetraprenyl-β-curcumene cyclase and a method for producing ambrein using the same. According to the present invention, ambrein can be efficiently produced. [Background technology]
[0002] Ambergris is a luxury fragrance that has been used around the world since around the 7th century, and is also used as a traditional Chinese medicine. It is thought that ambergris is produced when sperm whales turn indigestible food (octopus, squid, etc.) into stones using secretions from their digestive tract and excrete them, but the detailed mechanism of its production is unknown. The main component of ambergris is ambergris, which is thought to be oxidized and decomposed by sunlight and oxygen while floating on the sea, producing various compounds with aromas.
[0003] Amberine, the main component of ambergris, is used as a fragrance and medicine, but it is impossible to obtain it in large quantities from nature, so various organic synthesis methods have been proposed. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication WO2017 / 150695 Brochure [Patent Document 2] International Publication WO2019 / 045058 Brochure [Patent Document 3] International Publication WO2021 / 193806 Brochure Summary of the Invention [Problem to be solved by the invention]
[0005] The present inventors have discovered and proposed a method for obtaining ambrein from squalene in a two-step reaction using a single enzyme by using a mutant tetraprenyl-β-curcumene cyclase (D373C, etc.) (Patent Documents 1 to 3). However, these methods have room for improvement in terms of the production of ambrein, and a more efficient method for producing ambrein has been anticipated. Therefore, an object of the present invention is to provide a method for producing ambrein, which can easily and efficiently obtain ambrein. [Means for solving the problem]
[0006] The present inventors have conducted extensive research into a method for producing ambrein that can easily and efficiently produce ambrein, and have surprisingly found that a mutant tetraprenyl-β-curcumene cyclase having a slight specific mutation can efficiently produce a bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) from squalene in high yield. The present inventors have further found that a mutant tetraprenyl-β-curcumene cyclase having an amino acid such as D373C can efficiently produce ambrein from squalene in high yield. The present invention is based on these findings. Thus, the present invention provides [1] A mutant tetraprenyl-β-curcumene cyclase having one or more amino acids selected from the group consisting of (a) tryptophan, which is the seventh amino acid residue in the QXXXGX(F / W) motif, (b) aspartic acid, which is the ninth amino acid residue from the C-terminus of the TALXSYA motif, and (c) proline, which is the fifth amino acid residue in the NGLYXWP motif, (i) the mutant tetraprenyl-β-curcumene cyclase has a QXXXGX(W / F) motif located 100 or more amino acid residues away from the N-terminus of the DXDD motif, a NGLYXWP motif located 180 to 250 amino acid residues away from the N-terminus of the DXDD motif, an (A / S / G)RX(H / N)XXP motif located 180 to 250 amino acid residues away from the N-terminus of the DXDD motif, an (D / N)G(T / L)( a mutant tetraprenyl-β-curcumene cyclase having a L / F / Y)(Y / F)SY motif, a TALXSYA motif located 25 to 90 amino acid residues away from the N-terminus, a QXXXX(G / A / S)X(F / W / Y) motif located 10 to 50 amino acid residues away from the N-terminus, a QXXXGX(F / W / Y) motif located 20 to 50 amino acid residues away from the C-terminus, a QXXXGXW motif located 50 to 120 amino acid residues away from the C-terminus, a QXXXGX(F / W) motif located 120 to 170 amino acid residues away from the C-terminus, and the GXGX(G / A / P) motif located 180 to 250 amino acid residues away from the C-terminus, (ii) having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO:1, and (iii) exhibiting 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate; [2] The polypeptide constituting the mutant tetraprenyl-β-curcumene cyclase is (1) a polypeptide consisting of an amino acid sequence including, in the amino acid sequence represented by SEQ ID NO: 1, the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described in (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described in (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described in (c), or a combination of two or more of these substitutions; (2) a polypeptide consisting of, in the amino acid sequence represented by SEQ ID NO: 1, the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described in (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described in (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described in (c), or a combination of two or more of these substitutions. (3) a polypeptide having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added in an amino acid sequence other than the substituted (a), (b), and / or (c) of the amino acid sequence, and which exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate, the tryptophan of (a) at the 325th phenylalanine from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 being included in the amino acid sequence represented by SEQ ID NO:1, a substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid as described in (b), a substitution of glutamine at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline as described in (c), or a combination of two or more of these substitutions, the amino acid sequence having an identity of 80% or more to an amino acid sequence other than the substituted amino acid sequences (a), (b), and / or (c); and(4) a polypeptide exhibiting 21-triene generating activity, comprising an amino acid sequence represented by SEQ ID NO:1, which includes the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline as described above in (c), or a combination of two or more of these substitutions; or (5) a polypeptide exhibiting 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate, wherein in the amino acid sequence represented by SEQ ID NO:1, the phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 is replaced by the tryptophan in (a), the glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 is replaced by the aspartic acid in (b), or the glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 is replaced by the proline in (c), or (5) a polypeptide having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added in an amino acid sequence other than the substituted (a), (b), and / or (c) in the amino acid sequence, which includes substitutions of two or more of these combinations, and which exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate, or (6) a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 in which the 325th phenylalanine from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 is replaced by the tryptophan represented by (a), A polypeptide comprising an amino acid sequence having an identity of 80% or more with an amino acid sequence other than the substituted amino acid sequences (a), (b), and / or (c), which includes a substitution of the 325th glutamine from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the aspartic acid (b), a substitution of the 139th glutamic acid from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the proline (c), or a combination of two or more of these substitutions; and which exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate. The mutant tetraprenyl-β-curcumene cyclase according to [1], [3] The mutant tetraprenyl-β-curcumene cyclase according to [1] or [2], wherein the tryptophan in (a) is substituted with an amino acid other than tryptophan by tryptophan, the aspartic acid in (b) is substituted with an amino acid other than aspartic acid by aspartic acid, and the proline in (c) is substituted with an amino acid other than proline by proline. [4] The mutant tetraprenyl-β-curcumene cyclase according to [1], wherein the mutant tetraprenyl-β-curcumene cyclase is (1)(d) a cysteine at the fourth amino acid residue of the DXDD motif, (2)(d) a cysteine at the fourth amino acid residue of the DXDD motif, and (e) an alanine at the N-terminus of the (A / S / G)RX(H / N)XXP motif, (3)(d) a cysteine at the fourth amino acid residue of the DXDD motif, and (f) an alanine at the fourth amino acid residue of the GXGX(G / A / P) motif, or (4)(d) a cysteine at the fourth amino acid residue of the DXDD motif, (e) an alanine at the N-terminus of the (A / S / G)RX(H / N)XXP motif, and (f) an alanine at the fourth amino acid residue of the GXGX(G / A / P) motif, and exhibits ambrein-forming activity using squalene as a substrate. [5] The polypeptide constituting the mutant tetraprenyl-β-curcumene cyclase contains a substitution of the aspartic acid at the 327th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with the cysteine in (d), (1) A polypeptide consisting of an amino acid sequence represented by SEQ ID NO:1, which includes the substitution (a) of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan, the substitution (b) of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid, the substitution (c) of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline, or a combination of two or more of (a) to (c), and further includes the substitution (e) of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine, the substitution (f) of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine, or a combination of substitutions (e) and (f). (2) In the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence includes the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of the substitutions (a) to (c), and in the amino acid sequence represented by SEQ ID NO:1, a polypeptide having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted and / or added in an amino acid sequence other than the substituted (a), (b), (c), (d), (e) and / or (f) in the amino acid sequence represented by SEQ ID NO: 1, further comprising the substitution of tyrosine at the 167th position from the N-terminus with alanine as described in (e), the substitution of leucine at the 596th position from the N-terminus with alanine as described in (f), or a combination of substitutions (e) and (f); (3) In the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence includes the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of the substitutions (a) to (c), and is represented by SEQ ID NO:1. a polypeptide having an amino acid sequence which has an identity of 80% or more to an amino acid sequence other than the amino acid sequences substituted with (a), (b), (c), (d), (e) and / or (f), and which further comprises a substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described in (e), a substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described in (f), or a combination of substitutions (e) and (f); (4) A polypeptide comprising an amino acid sequence represented by SEQ ID NO:1, which includes the substitution (a) of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan, the substitution (b) of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid, the substitution (c) of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline, or a combination of two or more of (a) to (c), and further includes the substitution (e) of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine, the substitution (f) of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine, or a combination of substitutions (e) and (f), and which exhibits ambrain-producing activity using squalene as a substrate. (5) In the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence includes the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of the substitutions (a) to (c), and a polypeptide comprising an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted and / or added in an amino acid sequence other than the substituted (a), (b), (c), (d), (e) and / or (f) in the amino acid sequence represented by SEQ ID NO: 1, further comprising the substitution of tyrosine at the 167th position from the N-terminus with alanine as in (e), the substitution of leucine at the 596th position from the N-terminus with alanine as in (f), or a combination of substitutions (e) and (f); and further comprising an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted and / or added in an amino acid sequence other than the substituted (a), (b), (c), (d), (e) and / or (f), and which exhibits ambrain-producing activity using squalene as a substrate; (6) In the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence includes the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of the substitutions (a) to (c), and is represented by SEQ ID NO:1. a substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above (e), a substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above (f), or a combination of substitutions (e) and (f), said amino acid sequence having an identity of 80% or more to an amino acid sequence other than the substituted amino acids (a), (b), (c), (d), (e) and / or (f), and further exhibiting ambrain-forming activity using squalene as a substrate; The mutant tetraprenyl-β-curcumene cyclase according to [4], [6] The mutant tetraprenyl-β-curcumene cyclase according to [4] or [5], wherein the tryptophan in (a) is replaced by an amino acid other than tryptophan with tryptophan, the aspartic acid in (b) is replaced by an amino acid other than aspartic acid with aspartic acid, the proline in (c) is replaced by an amino acid other than proline with proline, the cysteine in (d) is replaced by an amino acid other than cysteine with cysteine, the alanine in (e) is replaced by an amino acid other than alanine with alanine, and the alanine in (f) is replaced by an amino acid other than alanine with alanine. [7] A polynucleotide encoding the mutant tetraprenyl-β-curcumene cyclase according to any one of [1] to [6]. [8] A microorganism having the polynucleotide according to [7]. [9] A vector comprising DNA having the polynucleotide according to [7].
[10] A transformant having the vector according to [9].
[11] A method for producing 8α-hydroxypolypoda-13,17,21-triene, comprising reacting the mutant tetraprenyl-β-curcumene cyclase according to any one of [1] to [3] with squalene to obtain 8α-hydroxypolypoda-13,17,21-triene.
[12] A method for producing ambrein, comprising reacting the mutant tetraprenyl-β-curcumene cyclase according to any one of [4] to [6] with squalene to obtain ambrein.
[13] A method for producing ambrein, comprising culturing the microorganism according to [8]; and
[14] A method for producing ambrein, comprising culturing the transformant according to
[10] . Regarding. Effect of the Invention
[0007] The mutant tetraprenyl-β-curcumene cyclase of the present invention has improved thermostability and can efficiently produce bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) and / or ambuline at higher temperatures than conventional ones. In particular, the enzyme activity can be improved at around 37° C., which is the average culture temperature of E. coli. [Brief description of the drawings]
[0008] [Figure 1] FIG. 1 is a graph showing the activity of wild-type tetraprenyl-β-curcumene cyclase (WT), E139P in which glutamic acid at position 139 is replaced by proline, Q325D in which glutamine at position 325 is replaced by asparagine, F530W in which phenylalanine at position 530 is replaced by tryptophan, and E139P / Q325D / F530W having these three substitutions to produce a bicyclic compound (8α-hydroxypolypoda-13,17,21-triene) at 36° C. using squalene as a substrate. [Diagram 2] 1 is a graph showing the activity of ambrein production at 36°C using squalene as a substrate for Y167A / D373C, Y167A / D373C / E139P, Y167A / D373C / Q325D, Y167A / D373C / F530W, and Y167A / D373C / E139P / Q325D / F530W, in which tyrosine at position 167 is replaced by alanine and aspartic acid at position 373 is replaced by cysteine. [Diagram 3] This is a graph showing the activity of wild-type tetraprenyl-β-curcumene cyclase (WT) and E139P / Q325D / F530W (EQF) to produce a bicyclic compound (8α-hydroxypolypoda-13,17,21-triene) using squalene as a substrate at 30°C, 33°C, or 36°C. [Figure 4-1]FIG. 1 shows the amino acid sequences of wild-type tetraprenyl-β-curcumene cyclase (WildType), E139P, Q325D, F530W, and E139P / Q325D / F530W, Y167A / D373C, Y167A / D373C / E139P, Y167A / D373C / Q325D, Y167A / D373C / F530W, Y167A / D373C / E139P / Q325D / F530W, and Y167A / D373C / L596A / E139P / Q325D / F530W. [Figure 4-2] FIG. 1 shows the amino acid sequences of wild-type tetraprenyl-β-curcumene cyclase (WildType), E139P, Q325D, F530W, and E139P / Q325D / F530W, Y167A / D373C, Y167A / D373C / E139P, Y167A / D373C / Q325D, Y167A / D373C / F530W, Y167A / D373C / E139P / Q325D / F530W, and Y167A / D373C / L596A / E139P / Q325D / F530W. [Figure 4-3] FIG. 1 shows the amino acid sequences of wild-type tetraprenyl-β-curcumene cyclase (WildType), E139P, Q325D, F530W, and E139P / Q325D / F530W, Y167A / D373C, Y167A / D373C / E139P, Y167A / D373C / Q325D, Y167A / D373C / F530W, Y167A / D373C / E139P / Q325D / F530W, and Y167A / D373C / L596A / E139P / Q325D / F530W. [Diagram 5] FIG. 1 shows the amino acid sequences of wild-type Bacillus megaterium, Priestia aryabhattai, and Bacillus Megaterium strain Q3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] (Tetraprenyl-β-curcumene cyclase) Wild-type tetraprenyl-β-curcumene cyclase (hereinafter sometimes referred to as wild-type TC) can generate ambrein using 3-deoxyachilleol A, which has a single ring at one end, as a substrate. That is, when tetraprenyl-β-curcumene cyclase uses 3-deoxyachilleol A as a substrate, it can selectively cyclize the uncyclized end of 3-deoxyachilleol A to generate a compound cyclized at both ends. Tetraprenyl-β-curcumene cyclase can also produce the bicyclic 8α-hydroxypolypoda-13,17,21-triene from squalene as a substrate. That is, tetraprenyl-β-curcumene cyclase is classified as EC 4.2.1.129 and is an enzyme that can catalyze the reaction of producing batiterpenol A from water and tetraprenyl-β-curcumene, or the reaction of producing 8α-hydroxypolypoda-13,17,21-triene from squalene. Tetraprenyl-β-curcumene cyclase is found in bacteria of the genus Bacillus, Brevibacillus, Paenibacillus, Geobacillus, etc. Examples of bacteria of the genus Bacillus include Bacillus subtilis, Bacillus megaterium, Priestia aryabhattai, and Bacillus licheniformis.
[0010] Tetraprenyl-β-curcumene cyclase has, based on the DXDD motif, a QXXXGX(W / F) motif located 100 or more amino acid residues away from the N-terminus, a NGLYXWP motif located 180 to 280 amino acid residues away from the N-terminus, the (A / S / G)RX(H / N)XXP motif located 180 to 250 amino acid residues away from the N-terminus, the (D / N)G(T / L)(L / F / Y)(Y / F)SY motif located 80 to 140 amino acid residues away from the N-terminus, and a (D / N)G(T / L)(L / F / Y)(Y / F)SY motif located 25 to 90 amino acid residues away from the N-terminus. It has a TALXSYA motif located at a distance from the amino acid residue, a QXXXX(G / A / S)X(F / W / Y) motif located 10 to 50 amino acid residues away on the N-terminus side, a QXXXGX(F / W / Y) motif located 20 to 50 amino acid residues away on the C-terminus side, a QXXXGXW motif located 50 to 120 amino acid residues away on the C-terminus side, a QXXXGX(F / W) motif located 120 to 170 amino acid residues away on the C-terminus side, and the GXGX(G / A / P) motif located 180 to 250 amino acid residues away on the C-terminus side. The term "DXDD motif" as used herein refers to a DXDD sequence including D372 (e.g., aspartic acid at position 372 in the tetraprenyl-β-curcumene cyclase of Bacillus megaterium represented by SEQ ID NO: 1), which catalyzes the initiation of the cyclization reaction in tetraprenyl-β-curcumene cyclase, and refers to a region that is highly conserved in tetraprenyl-β-curcumene cyclases of different origins. As used herein, "based on the DXDD motif" refers to specifying the position of each motif from the DXDD motif located on the C-terminal side from the center of the tetraprenyl-β-curcumene cyclase. For example, the QXXXGX(W / F) motif is located "at a position 100 amino acid residues or more away from the N-terminus of the DXDD motif", which means that the QXXXGX(W / F) motif is located at a position 100 amino acid residues or more away from the DXDD motif, with the amino acid residue adjacent to the N-terminus being set as 1.
[0011] [1] Mutant tetraprenyl-β-curcumene cyclase The mutant tetraprenyl-β-curcumene cyclase of the present invention is a mutant tetraprenyl-β-curcumene cyclase having one or more amino acids selected from the group consisting of: (a) tryptophan, which is the seventh amino acid residue in the QXXXGX(F / W) motif; (b) aspartic acid, which is the ninth amino acid residue from the C-terminus of the TALXSYA motif; and (c) proline, which is the fifth amino acid residue in the NGLYXWP motif; (i) The mutant tetraprenyl-β-curcumene cyclase has, based on the DXDD motif, a QXXXGX(W / F) motif at a position 100 or more amino acid residues away from the N-terminus, a NGLYXWP motif at a position 180 to 280 amino acid residues away from the N-terminus, a (A / S / G)RX(H / N)XXP motif at a position 180 to 250 amino acid residues away from the N-terminus, a (D / N)G(T / L)(L / F / Y)(Y / F)SY motif at a position 80 to 140 amino acid residues away from the N-terminus, and a (D / N)G(T / L)(L / F / Y)(Y / F)SY motif at a position 25 to 90 amino acid residues away from the N-terminus. a TALXSYA motif located 10 to 50 amino acid residues away from the N-terminus, a QXXXX(G / A / S)X(F / W / Y) motif located 20 to 50 amino acid residues away from the C-terminus, a QXXXGX(F / W / Y) motif located 50 to 120 amino acid residues away from the C-terminus, a QXXXGXW motif located 120 to 170 amino acid residues away from the C-terminus, and the GXGX(G / A / P) motif located 180 to 250 amino acid residues away from the C-terminus, (ii) having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO:1; and (iii) It exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate. The enzyme activity "exhibiting 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate" is not limited as long as the activity can be detected by a method for measuring enzyme activity used in the field, such as gas chromatography, HPLC, or TLC. For example, in the method using gas chromatography in Production Method Example 1, the squalene solution and the enzyme solution are incubated, for example, for 64 hours at 30° C. The enzyme reaction is stopped, and the production activity of 8α-hydroxypolypoda-13,17,21-triene can be measured by gas chromatography. Furthermore, the enzyme activity "exhibiting ambrein-forming activity using squalene as a substrate" is not limited as long as the activity can be detected by a method for measuring enzyme activity used in the art, such as gas chromatography, HPLC, or TLC. For example, in the method using gas chromatography in Production Method 2, the squalene solution and the enzyme solution are incubated for 64 hours at 30° C. The enzyme reaction is stopped, and the production activity of ambrein can be measured by gas chromatography.
[0012] Here, the alphabets defining each motif and sequence represent one-letter abbreviations of amino acids, and "X" means any amino acid. That is, in the case of a QXXXGX(W / F) motif, it indicates that from the N-terminus to the C-terminus, glutamine (Q), three arbitrary amino acids (X), glycine (G), an arbitrary amino acid (X), and either tryptophan (W) or phenylalanine (F) are arranged. In addition, "having a QXXXGX(W / F) motif at a position 100 or more amino acid residues away from the N-terminus based on the DXDD motif" means that there are 100 or more amino acid residues between the DXDD motif and the QXXXGX(W / F) motif, and the same applies to the specification of other motifs. The fourth amino acid in the GXGX (G / A / P) motif refers to the fourth amino acid counting from the N-terminus, and the same applies to other sequences. Hereinafter, the same applies unless otherwise specified. The ninth amino acid from the C-terminus of the ALXSYA motif refers to the ninth amino acid, with the amino acid next to the A at the C-terminus of the ALXSYA motif being number 1, and the same applies to other sequences. Hereinafter, the same applies unless otherwise specified. The identity of amino acid sequences is determined by aligning the sequences to be compared by inserting appropriate gaps so that the amino acid residues match, dividing the number of matching amino acid residues by the total number of amino acid residues, and expressing the percentage. Identity can be determined using well-known programs (e.g., BLAST, FASTA, CLUSTAL W, etc.).
[0013] The mutant tetraprenyl-β-curcumene cyclase of the present invention preferably has at least one amino acid selected from (a) tryptophan, (b) aspartic acid, or (c) proline, but is not limited thereto, and more preferably has a combination of two amino acids (e.g., a combination of (a) tryptophan and (b) aspartic acid, a combination of (a) tryptophan and (c) proline, or a combination of (b) aspartic acid and (c) proline), and even more preferably has a combination of three amino acids (a combination of (a) tryptophan, (b) aspartic acid, and (c) proline). By having these amino acids, the mutant tetraprenyl-β-curcumene cyclase of the present invention has improved heat resistance and improved enzyme activity.
[0014] The mutant tetraprenyl-β-curcumene cyclase of the present invention is preferably, but not limited to, the tryptophan in (a) is replaced by an amino acid other than tryptophan, the aspartic acid in (b) is replaced by an amino acid other than aspartic acid, and the proline in (c) is replaced by an amino acid other than proline. For example, in the tetraprenyl-β-curcumene cyclase of Bacillus megaterium represented by SEQ ID NO: 1, the original amino acid in (a) is phenylalanine (F), the original amino acid in (b) is glutamine, and the original amino acid in (c) is glutamic acid (E). In the tetraprenyl-β-curcumene cyclase of Bacillus megaterium, preferably, the phenylalanine in (a) is replaced by tryptophan (W), the native glutamine in (b) is replaced by aspartic acid (D), and the glutamic acid (E) in (c) is replaced by proline (P).
[0015] The mutant tetraprenyl-β-curcumene cyclase of the present invention has one or more of (a) tryptophan, (b) aspartic acid, or (c) proline, and is thereby capable of efficiently producing a bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) from squalene in high yield.
[0016] (a) Tryptophan, the seventh amino acid residue in the QXXXGX(F / W) motif The tryptophan in (a) of the present invention is the seventh amino acid residue in the QXXXGX(F / W) motif of tetraprenyl-β-curcumene cyclase. The tryptophan in (a) may be, but is not limited to, an amino acid other than tryptophan substituted with tryptophan. Examples of the amino acid other than tryptophan include alanine, cysteine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tyrosine, and aspartic acid. Because the seventh amino acid residue of the QXXXGX(F / W) motif is tryptophan, the mutant tetraprenyl-β-curcumene cyclase of the present invention has improved function of producing a bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) from squalene. The QXXXGX(F / W) motif is present, for example, at positions 524 to 530 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 524 to 530 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 521 to 527 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0017] (b) The ninth aspartic acid from the C-terminus of the TALXSYA motif The aspartic acid of (b) of the present invention is the ninth amino acid residue from the C-terminus of the ALXSYA motif of tetraprenyl-β-curcumene cyclase. The aspartic acid of (b) is not limited, but may be one in which an amino acid other than aspartic acid is substituted with aspartic acid. Examples of the amino acid other than aspartic acid include alanine, cysteine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, and proline. Because the ninth amino acid residue from the C-terminus of the TALXSYA motif is proline, the mutant tetraprenyl-β-curcumene cyclase of the present invention has improved function of producing a bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) from squalene. The TALXSYA motif is present, for example, at positions 310 to 316 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 310 to 316 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 307 to 313 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0018] (c) Proline, the fifth amino acid residue in the NGLYXWP motif The proline (c) of the present invention is the fifth amino acid residue of the NGLYXWP motif of tetraprenyl-β-curcumene cyclase. The proline (c) may be, but is not limited to, an amino acid other than proline substituted with proline. Examples of the amino acid other than proline include alanine, cysteine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, and aspartic acid. Because the fifth amino acid residue of the NGLYXWP motif is proline, the mutant tetraprenyl-β-curcumene cyclase of the present invention has improved function of producing a bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) from squalene. The NGLYXWP motif is present, for example, at positions 135 to 141 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 135 to 141 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 132 to 138 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0019] The mutant tetraprenyl-β-curcumene cyclase of the present invention is not limited, but preferably (1)(d) the fourth amino acid residue of the DXDD motif may be cysteine. Also, (2)(d) the fourth amino acid residue of the DXDD motif may be cysteine, and (e) the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif may be alanine. Also, (3)(d) the fourth amino acid residue of the DXDD motif may be cysteine, and (f) the fourth amino acid residue of the GXGX(G / A / P) motif may be alanine. Furthermore, (4)(d) the fourth amino acid residue of the DXDD motif may be cysteine, (e) the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif may be alanine, and (f) the fourth amino acid residue of the GXGX(G / A / P) motif may be alanine. However, the mutant tetraprenyl-β-curcumene cyclase having the (d) cysteine, and (e) alanine, and / or (f) alanine has one or more of (a) tryptophan, (b) aspartic acid, or (c) proline.
[0020] (d) Cysteine, the fourth amino acid residue in the DXDD motif The cysteine (d) of the present invention is the fourth amino acid residue of the DXDD motif of tetraprenyl-β-curcumene cyclase. The cysteine (d) may be, but is not limited to, an amino acid other than cysteine substituted with cysteine. Examples of the amino acid other than cysteine include alanine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, proline, and aspartic acid. Because the fourth amino acid residue of the DXDD motif is cysteine, the mutant tetraprenyl-β-curcumene cyclase of the present invention can produce 3-deoxyachilleol A from squalene and ambrein from 8α-hydroxypolypoda-13,17,21-triene. The DXDD motif is present, for example, at positions 370 to 373 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 370 to 373 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 367 to 370 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0021] (e) Alanine, the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif The alanine (e) of the present invention is an amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif of tetraprenyl-β-curcumene cyclase. The alanine (e) is not limited, and may be one in which an amino acid other than alanine is substituted with alanine. Examples of the amino acid other than alanine include cysteine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, proline, and aspartic acid. Because the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif is alanine, the mutant tetraprenyl-β-curcumene cyclase of the present invention has improved functions of producing 3-deoxyachilleol A from squalene and of producing ambrein from 8α-hydroxypolypoda-13,17,21-triene. The (A / S / G)RX(H / N)XXP motif is present, for example, at positions 168 to 174 from the N-terminus of the amino acid sequence of tetraprenyl-β-curcumene cyclase from Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 168 to 174 from the N-terminus of the amino acid sequence of tetraprenyl-β-curcumene cyclase from Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 165 to 171 from the N-terminus of the amino acid sequence of tetraprenyl-β-curcumene cyclase from Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0022] (f) Alanine, the fourth amino acid residue in the GXGX(G / A / P) motif The alanine of (f) of the present invention is the fourth amino acid residue in the (GXGX(G / A / P) motif of tetraprenyl-β-curcumene cyclase. The alanine of (f) is not limited to, and may be an amino acid other than alanine substituted with alanine. Examples of amino acids other than alanine include cysteine, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, proline, and aspartic acid. (Since the fourth amino acid residue of the GXGX(G / A / P) motif is alanine, the mutant tetraprenyl-β-curcumene cyclase of the present invention has an improved function of producing ambrein from 8α-hydroxypolypoda-13,17,21-triene. (The GXGX(G / A / P) motif is present, for example, at positions 593 to 597 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium shown in SEQ ID NO: 1. It is also present at positions 593 to 597 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Priestia aryabhattai shown in SEQ ID NO: 2. It is present at positions 590 to 594 from the N-terminus of the amino acid sequence of the tetraprenyl-β-curcumene cyclase of Bacillus megaterium strain Q3 shown in SEQ ID NO: 3.
[0023] FIG. 4 shows the tetraprenyl-β-curcumene cyclase of the wild type (WildType) (SEQ ID NO: 1) and the tetraprenyl-β-curcumene cyclase of the present invention, E139P (SEQ ID NO: 4), Q325D (SEQ ID NO: 5), F530W (SEQ ID NO: 6), and E139P / Q325D / F530W (SEQ ID NO: 7), Y167A / D373C (SEQ ID NO: 8), Y167A / D373C (SEQ ID NO: 9), Y167A / D373C (SEQ ID NO: 10), Y167A / D373C (SEQ ID NO: 11), Y167A / D373C (SEQ ID NO: 12), and Y167A / D373C (SEQ ID NO: 13). The amino acid sequences of 73C / E139P (sequence number 9), Y167A / D373C / Q325D (sequence number 10), Y167A / D373C / F530W (sequence number 11), Y167A / D373C / E139P / Q325D / F530W (sequence number 12), and Y167A / D373C / L596A / E139P / Q325D / F530W (sequence number 13) are shown. FIG. 5 shows the amino acid sequences of wild-type Bacillus megaterium (SEQ ID NO: 1), Priestia aryabhattai (SEQ ID NO: 2), and Bacillus megaterium strain Q3 (SEQ ID NO: 3).
[0024] (An amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added) The mutant tetraprenyl-β-curcumene cyclase polypeptide of the present invention may be a polypeptide consisting of an amino acid sequence in which one or several amino acids are deleted, substituted, inserted, and / or added in the amino acid sequence of SEQ ID NO: 1. However, the mutant tetraprenyl-β-curcumene cyclase has at least one of (a) tryptophan, (b) aspartic acid, and (c) proline in addition to the above. The mutant tetraprenyl-β-curcumene cyclase polypeptide of the present invention is a polypeptide that exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate. In other words, a polypeptide that does not exhibit 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate is not included in the mutant tetraprenyl-β-curcumene cyclase polypeptide of the present invention. In the present specification, "an amino acid sequence in which one or several amino acids are deleted, substituted, inserted, and / or added" means that the amino acid sequence has been modified by amino acid substitution or the like. The number of amino acid modifications can be, for example, 1 to 330, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 100, or 1 to 50, and is preferably 1 to 30, more preferably 1 to 10, even more preferably 1 to 5, and most preferably 1 to 2. An example of a modified amino acid sequence of a mutant peptide that can be used in the present invention can be an amino acid sequence in which the amino acids have one or several (preferably 1, 2, 3, or 4) conservative substitutions. In the mutant tetraprenyl-β-curcumene cyclase of the present invention, even if multiple amino acids at the N-terminus and / or multiple amino acids at the C-terminus are deleted, the mutant tetraprenyl-β-curcumene cyclase of the present invention is included in the mutant tetraprenyl-β-curcumene cyclase of the present invention, so long as the heat-resistant skeleton is not destroyed. Specifically, 25 amino acid residues may be deleted from the N-terminus, and the number of amine residues deleted is preferably 24 residues (N-terminal helix structure), more preferably 7 residues (hydrophobic core region of MIILLKE), even more preferably 5 residues (MIILL), and even more preferably 3 residues (MII). 25 amino acid residues may be deleted from the C-terminus, and the number of amine residues deleted is preferably 7 residues (YAKKHSS), more preferably 2 residues (SS).
[0025] (Amino acid sequence with 50% or more identity to amino acid sequence) The mutant tetraprenyl-β-curcumene cyclase polypeptide of the present invention may be a polypeptide consisting of an amino acid sequence having an identity of 50% or more with respect to the amino acid sequence of SEQ ID NO: 1. However, the mutant tetraprenyl-β-curcumene cyclase has at least one of (a) tryptophan, (b) aspartic acid, and (c) proline in addition to the above. Furthermore, for example, when (a) is tryptophan, (b) is aspartic acid, (c) is proline, (d) is cysteine, (e) is alanine, and / or (f) is alanine, the identity of the amino acid sequence excluding these amino acids is meant. The mutant tetraprenyl-β-curcumene cyclase polypeptide of the present invention is a polypeptide that exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate. That is, a polypeptide that does not show 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate is not included in the polypeptide of the mutant tetraprenyl-β-curcumene cyclase of the present invention. The mutant tetraprenyl-β-curcumene cyclase is preferably a polypeptide consisting of an amino acid sequence having an identity of 50% or more, more preferably an amino acid sequence having an identity of 60% or more, more preferably an amino acid sequence having an identity of 70% or more, more preferably an amino acid sequence having an identity of 80% or more, more preferably an amino acid sequence having an identity of 83% or more, more preferably an amino acid sequence having an identity of 85% or more, more preferably an amino acid sequence having an identity of 88% or more, more preferably an amino acid sequence having an identity of 90% or more, more preferably an amino acid sequence having an amino acid sequence having an identity of 93% or more, more preferably an amino acid sequence having an identity of 95% or more, more preferably an amino acid sequence having an identity of 98% or more, and most preferably an amino acid sequence having an identity of 99% or more, and consisting of or including a polypeptide that shows 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate.
[0026] The "amino acid sequence in which one or several amino acids are deleted, substituted, inserted, and / or added" or the "amino acid sequence having an identity of 80% or more" in the amino acid sequence of SEQ ID NO: 1 is a substitution of the amino acid sequence of SEQ ID NO: 1, and this substitution of the amino acid sequence is a conservative substitution that maintains the function of the mutant tetraprenyl-β-curcumene cyclase of the present invention. In other words, "conservative substitution" means a substitution that does not lose the excellent effect of the mutant tetraprenyl-β-curcumene cyclase of the present invention. That is, even in the case of the insertion, substitution, deletion, or addition, it is a substitution that can improve the 8α-hydroxypolypoda-13,17,21-triene production activity using squalene as a substrate. Specifically, it means replacing an amino acid residue with another chemically similar amino acid residue. For example, a hydrophobic residue may be replaced with another hydrophobic residue, or a polar residue may be replaced with another polar residue having the same charge. Functionally similar amino acids that can be obtained by such substitutions are known in the art for each amino acid. Examples of non-polar (hydrophobic) amino acids include alanine, valine, isoleucine, leucine, proline, tryptophan, phenylalanine, and methionine. Examples of polar (neutral) amino acids include glycine, serine, threonine, tyrosine, glutamine, asparagine, and cysteine. Examples of positively charged (basic) amino acids include arginine, histidine, and lysine. Examples of negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
[0027] In the mutant tetraprenyl-β-curcumene cyclase of the present invention, (a) changing the seventh amino acid residue of the QXXXGX(F / W) motif to tryptophan, (b) changing the ninth amino acid residue from the C-terminus of the TALXSYA motif to aspartic acid, and (c) changing the fifth amino acid residue of the NGLYXWP motif to proline are active substitutions (mutations) for improving heat resistance and efficiently producing bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) and / or ambulain at higher temperatures than conventional ones, while the above conservative substitutions are substitutions for maintaining the activity of producing bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) and / or ambulain, and can be easily performed by a person skilled in the art.
[0028] The mutant tetraprenyl-β-curcumene cyclase of the present invention can be obtained using known gene recombination techniques. For example, chromosomal DNA of Bacillus megaterium is obtained, and the tetraprenyl-β-curcumene cyclase is amplified by PCR or the like using appropriate primers. The obtained gene is inserted into an appropriate vector, and the gene sequence is determined. Then, by introducing the above mutation, a gene encoding the mutant tetraprenyl-β-curcumene cyclase of the present invention can be obtained. The mutant tetraprenyl-β-curcumene cyclase of the present invention can be obtained by inserting the gene into a host such as yeast and expressing it. In addition, tetraprenyl-β-curcumene cyclase is known to exist in bacteria of the genus Bacillus in addition to Bacillus megaterium, and it is possible to obtain the enzyme derived from Bacillus subtilis, Bacillus licheniformis, Priestia aryabhattai, etc.
[0029] The gene encoding the mutant tetraprenyl-β-curcumene cyclase of the present invention can also be synthesized by a known synthetic gene synthesis method, and the mutant tetraprenyl-β-curcumene cyclase of the present invention can be obtained by expressing the synthesized gene.
[0030] (action) The mechanism by which the mutant tetraprenyl-β-curcumene cyclase of the present invention exhibits heat resistance and improved enzyme activity has not been analyzed in detail, but can be presumed as follows, although the present invention is not limited to the following presumption. It is presumed that (a) the amino acid residue near the 7th residue of the QXXXGX(F / W) motif, (b) the amino acid residue near the 9th residue from the C-terminus of the TALXSYA motif, and (c) the amino acid residue near the 5th residue of the NGLYXWP motif in tetraprenyl-β-curcumene cyclase affect the thermostability of tetraprenyl-β-curcumene cyclase. In particular, it is presumed that the tetraprenyl-β-curcumene cyclase is stabilized and its thermostability is improved by the fact that (a) the 7th amino acid residue of the QXXXGX(F / W) motif is tryptophan, (b) the 9th amino acid residue from the C-terminus of the TALXSYA motif is aspartic acid, and (c) the 5th amino acid residue of the NGLYXWP motif is proline.
[0031] [2] Polynucleotides The polynucleotide of the present invention is not particularly limited as long as it is a polynucleotide that encodes the tetraprenyl-β-curcumene cyclase of the present invention. For example, the polynucleotide may be a polynucleotide that encodes the polypeptides represented by SEQ ID NOs: 4 to 13. Further examples include polynucleotides that hybridize under stringent conditions with any one of the polynucleotides encoding the polypeptides shown in SEQ ID NOs: 4 to 13 and have the activity of producing ambrein from 8α-hydroxypolypoda-13,17,21-triene. Note that the term "polynucleotide" in this specification includes both DNA and RNA. Furthermore, it is preferable that the polynucleotide of the present invention is modified to have an optimal codon sequence suited to the microorganism or host cell into which it is introduced.
[0032] [3] Microorganisms The microorganism of the present invention is a microorganism having the polynucleotide of the present invention, i.e., is not particularly limited as long as it contains the polynucleotide of the present invention in its cells, and examples thereof include Escherichia coli, Bacillus subtilis, Brevibacillus sp., actinomycetes, baker's yeast, Aspergillus oryzae, and Neurospora crassa.
[0033] [4] Vector The vector of the present invention is a vector containing a DNA having a polynucleotide encoding the mutant tetraprenyl-β-curcumene cyclase. That is, the vector of the present invention is not particularly limited as long as it contains the polynucleotide of the present invention, and examples thereof include vectors obtained by inserting the polynucleotide of the present invention into a known expression vector appropriately selected depending on the host cell to be used. The expression vector is preferably one that can autonomously replicate or be integrated into a chromosome in a host such as Escherichia coli or baker's yeast, and has high expression efficiency for a foreign protein. The expression vector for expressing the polynucleotide is preferably a recombinant vector that can autonomously replicate in a microorganism and is composed of a promoter, a ribosome binding sequence, the DNA, and a transcription termination sequence. It may also contain a gene that controls the promoter.
[0034] More specifically, examples of the expression vectors include pBTrp2, pBTac1, pBTac2 (all commercially available from Boehringer Mannheim), pKK233-2 (Pharmacia), pSE280 (Invitrogen), pGEMEX-1 (Promega), pQE-8 (QIAGEN), pQE-30 (QIAGEN), pKYP10 (JP Patent Publication 58-110600), pKYP200 [Agricultural Biological Chemistry, 48, 669 (1984)], pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)], pBluescriptII SK+, pBluescriptII SK(-) (Stratagene), pTrS30 (FERM BP-5407), pTrS32 (FERM BP-5408), pGEX (Pharmacia), pET-3 (Novagen), pTerm2 (US4686191, US4939094, US5160735), pSupex, pUB110, pTP5, pC194, pUC18 [Gene, 33, 103 (1985)], pUC19 [Gene, 33, 103 (1985)], pSTV28 ( Examples of such vectors include pSTV29 (manufactured by Takara Shuzo Co., Ltd.), pSTV29 (manufactured by Takara Shuzo Co., Ltd.), pUC118 (manufactured by Takara Shuzo Co., Ltd.), pPA1 (JP Patent Publication No. 63-233798), pEG400 [J. Bacteriol., 172, 2392 (1990)], pColdI, pColdII, pColdIII, pColdIV, pNIDNA, and pNI-HisDNA (manufactured by Takara Bio Inc.).
[0035] The promoter may be any promoter that can be expressed in the host cells such as E. coli and baker's yeast. Examples of the promoter include promoters derived from E. coli or phages, such as the trp promoter (Ptrp), lac promoter (Plac), PL promoter, PR promoter, and PSE promoter, as well as SPO1 promoter, SPO2 promoter, and penP promoter. In addition, artificially designed and modified promoters such as the promoter (Ptrpx2) in which two Ptrp promoters are arranged in series, the tac promoter, the letI promoter, and the lacT7 promoter can also be used. To produce an enzyme used in the enzymatic production (synthesis in vitro by an enzymatic reaction using squalene as a substrate), a promoter that functions as a strong promoter and is capable of mass production of the target protein is preferred, and an inducible promoter is more preferred. Examples of the inducible promoter include the promoter of the cold shock gene cspA, whose expression is induced at low temperature, and the T7 promoter, which is induced by the addition of the inducer IPTG. In fermentation production (biosynthesis in vivo by a host using glucose or the like as a carbon source), among the above promoters, a promoter that constantly expresses the target gene regardless of tissue, i.e., a constitutive promoter, is more preferable. Examples of constitutive promoters include the promoters of the alcohol dehydrogenase 1 gene (ADH1), translation elongation factor TF-1α gene (TEF1), phosphoglycerate kinase gene (PGK1), triosephosphate isomerase gene (TPI1), triosephosphate dehydrogenase gene (TDH3), and pyruvate kinase gene (PYK1).
[0036] [5] Transformants The transformant of the present invention is not particularly limited as long as it contains the polynucleotide of the present invention, and may be, for example, a transformant in which the polynucleotide of the present invention is integrated into the chromosome of a host cell, or a transformant containing the polynucleotide of the present invention in the form of a vector. The transformant may also be a transformant expressing the polypeptide of the present invention, or a transformant not expressing the polypeptide of the present invention. The transformant of the present invention can be obtained, for example, by transforming a desired host cell with the vector of the present invention or with the polynucleotide of the present invention itself.
[0037] The host cell is not particularly limited, but is preferably an easily handled strain such as Escherichia coli, Bacillus subtilis, Brevibacillus sp., actinomycetes, yeast, Aspergillus oryzae, Neurospora crassa, etc., but it is also possible to use insect cells, plant cells, animal cells, etc. However, to produce an enzyme used in the enzymatic production (synthesis in vitro by an enzymatic reaction using squalene as a substrate), Escherichia coli, Bacillus subtilis, Brevibacillus sp., Aspergillus oryzae are preferred, and Escherichia coli is the most preferred. Also, for fermentation production (biosynthesis in vivo by a host using glucose or the like as a carbon source), yeast is the most preferred. The most preferred yeast strain is sake yeast. Particularly preferred are sake yeast Kyokai No. 7 or No. 701. Kyokai No. 701 yeast is a non-foaming yeast bred from Kyokai No. 7 and has the characteristic of not forming a high foam, but other properties are the same.
[0038] [6] Method for producing 8α-hydroxypolypoda-13,17,21-triene or ambrein The method for producing 8α-hydroxypolypoda-13,17,21-triene of the present invention comprises reacting the mutant tetraprenyl-β-curcumene cyclase with squalene to obtain 8α-hydroxypolypoda-13,17,21-triene. The method for producing ambrein of the present invention comprises reacting the mutant tetraprenyl-β-curcumene cyclase with squalene to obtain ambrein. The mutant tetraprenyl-β-curcumene cyclase used in the method for producing 8α-hydroxypolypoda-13,17,21-triene may have at least one of (a) tryptophan, which is the seventh amino acid residue in the QXXXGX(F / W) motif, (b) aspartic acid, which is the ninth amino acid residue from the C-terminus of the TALXSYA motif, or (c) proline, which is the fifth amino acid residue in the NGLYXWP motif. The mutant tetraprenyl-β-curcumene cyclase used in the method for producing ambrain may have (d) a cysteine as the fourth amino acid residue in the DXDD motif, and at least one or more of (a) tryptophan as the seventh amino acid residue in the QXXXGX(F / W) motif, (b) aspartic acid as the ninth amino acid residue from the C-terminus of the TALXSYA motif, or (c) proline as the fifth amino acid residue in the NGLYXWP motif.
[0039] The mutant tetraprenyl-β-curcumene cyclase can be produced by culturing a transformant obtained by introducing an enzyme expression vector into bacteria or the like. The medium used for culturing the transformant may be a commonly used medium and is appropriately selected depending on the type of host. For example, when culturing Escherichia coli, LB medium or the like is used. The medium may contain an antibiotic depending on the type of selection marker.
[0040] The mutant tetraprenyl-β-curcumene cyclase may be obtained by extracting and purifying the enzyme from a culture solution obtained by culturing a transformant capable of expressing the enzyme. Alternatively, the mutant tetraprenyl-β-curcumene cyclase of the present invention may be expressed as a fusion protein by fusing a trigger factor (TF) or a His tag to the N-terminus or C-terminus of the polypeptide to facilitate purification. Alternatively, an extract containing the enzyme extracted from the transformant in the culture solution may be used as is. A known method may be used to extract the enzyme from the transformant. The enzyme extraction step may include, for example, disrupting the transformant in an extraction solvent and separating the cell contents from the transformant fragments. The obtained cell contents contain the mutant tetraprenyl-β-curcumene cyclase of interest.
[0041] The method for disrupting the transformant may be a known method capable of disrupting the transformant and recovering the enzyme solution, such as ultrasonic disruption, glass bead disruption, etc. The conditions for disruption are not particularly limited, and may be at 10° C. or lower for 15 minutes, etc., as long as the enzyme is not inactivated. Methods for separating the intracellular contents from the microbial debris include sedimentation, centrifugation, filtration, and combinations of two or more of these separation methods. Separation conditions using these methods are known to those skilled in the art, and in the case of centrifugation, for example, 8,000×g to 15,000×g and 10 minutes to 20 minutes.
[0042] The extraction solvent may be any solvent commonly used for enzyme extraction, such as Tris-HCl buffer, potassium phosphate buffer, etc. The pH of the extraction solvent is preferably 3 to 10, more preferably 6 to 8, from the viewpoint of enzyme stability.
[0043] The extraction solvent may contain a surfactant. Examples of the surfactant include nonionic surfactants and zwitterionic surfactants. Examples of the nonionic surfactant include polyoxyethylene sorbitan fatty acid esters such as poly(oxyethylene) sorbitan monooleate (Tween 80), alkyl glucosides such as n-octyl β-D-glucoside, sucrose fatty acid esters such as sucrose stearate, and polyglycerin fatty acid esters such as polyglycerin stearate. Examples of the zwitterionic surfactant include N,N-dimethyl-N-dodecylglycine betaine, which is an alkyl betaine. In addition to these, surfactants commonly used in the art, such as Triton (registered trademark) X-100 (Triton X-100), polyoxyethylene (20) cetyl ether (Brij-58), and nonylphenol ethoxylate (Tergitol NP-40), can be used. From the viewpoint of enzyme stability, the concentration of the surfactant in the extraction solvent is preferably 0.001% by mass to 10% by mass, more preferably 0.10% by mass to 3.0% by mass, and even more preferably 0.10% by mass to 1.0% by mass.
[0044] From the viewpoint of enzyme activity, the extraction solvent preferably contains a reducing agent such as dithiothreitol or β-mercaptoethanol. As the reducing agent, dithiothreitol is preferable. The concentration of dithiothreitol in the extraction solvent is preferably 0.1 mM to 1 M, more preferably 1 mM to 10 mM. The presence of dithiothreitol in the extraction solvent tends to facilitate the retention of structures such as disulfide bonds in the enzyme, and thus the enzyme activity tends to increase.
[0045] From the viewpoint of enzyme activity, the extraction solvent preferably contains a chelating agent such as ethylenediaminetetraacetic acid (EDTA). The concentration of EDTA in the extraction solvent is preferably 0.01 mM to 1 M, more preferably 0.1 mM to 10 mM. The presence of EDTA in the extraction solvent chelates metal ions that may reduce enzyme activity, so that enzyme activity tends to be further increased.
[0046] In addition to the above components, the extraction solvent may contain known components that can be added to enzyme extraction solvents.
[0047] The mutant tetraprenyl-β-curcumene cyclase may be used alone or in combination of two or more kinds. The conditions for the reaction of mutant tetraprenyl-β-curcumene cyclase with squalene or 8α-hydroxypolypoda-13,17,21-triene are not particularly limited as long as the enzyme reaction can proceed. For example, the reaction temperature and reaction time can be appropriately selected based on the activity of mutant tetraprenyl-β-curcumene cyclase. From the viewpoint of reaction efficiency, the reaction temperature and reaction time are, for example, 4° C. to 100° C. and 1 hour to 30 days, and preferably 30° C. to 60° C. and 16 hours to 20 days. From the viewpoint of reaction efficiency, the pH condition is, for example, 3 to 10, and preferably 6 to 8.
[0048] The reaction solvent is not particularly limited as long as it does not inhibit the enzyme reaction, and a commonly used buffer solution or the like can be used. In addition, for example, the same solvent as the extraction solvent used in the enzyme extraction step can be used. In addition, an extract containing a mutant tetraprenyl-β-curcumene cyclase (e.g., a cell-free extract) may be used as it is as an enzyme solution in the reaction.
[0049] From the viewpoint of reaction efficiency, the concentration ratio of the mutant tetraprenyl-β-curcumene cyclase to its substrate, squalene, in the ambreine production reaction or the 8α-hydroxypolypoda-13,17,21-triene production reaction is preferably 1 to 10,000, more preferably 10 to 5,000, more preferably 100 to 3,000, and even more preferably 1,000 to 2,000, as the molar concentration ratio of substrate to enzyme (substrate / enzyme). From the viewpoint of reaction efficiency, the concentration of squalene used in the enzyme reaction is preferably 0.000001% by mass to 10% by mass, and more preferably 0.00001% by mass to 1% by mass, based on the total mass of the reaction solvent.
[0050] The reaction step in which mutant tetraprenyl-β-curcumene cyclase reacts with squalene may be repeated multiple times. This can increase the yield of ambrein or 8α-hydroxypolypoda-13,17,21-triene. When the reaction step is repeated multiple times, it may include a step of reintroducing squalene as a substrate into the reaction system, a step of inactivating the enzyme by a known method, and then recovering and purifying the reaction product in the reaction solution. When squalene is reintroduced, the timing and amount of squalene to be added can be appropriately set depending on the concentration of mutant tetraprenyl-β-curcumene cyclase in the reaction solution, the amount of substrate remaining in the reaction solution, etc.
[0051] Another embodiment of the method for producing ambulin of the present invention is characterized by culturing the microorganism or transformant of the present invention. Ambrein or 8α-hydroxypolypoda-13,17,21-triene can be produced by culturing the microorganism or the host cell transformed with the expression vector. For example, in the case of yeast, the yeast may be cultured in a commonly used YPD medium or the like. The yeast into which a gene has been introduced by homologous recombination or the yeast having an expression vector is pre-cultured, and then inoculated into a YPD medium or the like and cultured for 24 to 240 hours, preferably 72 to 120 hours. Ambrein secreted into the medium can be used as it is, or after purification by a known method. Specific examples of the purification method include solvent extraction, recrystallization, distillation, column chromatography, and HPLC. EXAMPLES
[0052] The present invention will be described in detail below with reference to examples, but the scope of the present invention is not limited thereto. In the text or figures, Bacillus megaterium may be abbreviated as "Bme", and tetraprenyl-β-curcumene cyclase derived from Bacillus megaterium may be abbreviated as "BmeTC".
[0053] Example 1 In this example, cloning of a mutant tetraprenyl-β-curcumene cyclase was performed, and a mutant tetraprenyl-β-curcumene cyclase gene in which glutamic acid at position 139 was substituted with proline was constructed. Using Bacillus megaterium chromosomal DNA as a template, a polynucleotide encoding wild-type tetraprenyl-β-curcumene cyclase was obtained by PCR, and the amino acid sequence of the wild-type enzyme was determined. (Unless otherwise specified, tetraprenyl-β-curcumene cyclase is a sequence derived from Bacillus megaterium, and may simply be referred to as "wild-type.") The obtained gene was inserted into the cloning site (restriction enzyme NdeI / XhoI site) of vector pColdI (Takara Bio Inc.) to obtain an expression vector containing the wild-type tetraprenyl-β-curcumene cyclase gene (SEQ ID NO: 1). A transformant of E. coli BL21(DE3) was prepared using the expression vector containing the obtained mutant tetraprenyl-β-curcumene cyclase gene. Next, a mutant tetraprenyl-β-curcumene cyclase gene in which glutamic acid at position 139 was replaced with proline was constructed. First, based on the gene sequence of tetraprenyl-β-curcumene cyclase (wild type), it was designed so that glutamic acid at position 139 was replaced with proline, and the gene was synthesized by optimizing the codons for the host Escherichia coli. The synthesized gene was inserted into the cloning site (restriction enzyme NdeI / XhoI sites) of the vector pColdI (Takara Bio Inc.). Using this vector gene as a template, the E139P forward primer: CGGTCTATAC was inserted so that glutamic acid at position 139 was replaced with proline. CCG TGGCCAAAGCTATTTTACCTCCC (SEQ ID NO: 14) and E139P reverse primer: GGGAGGTAAAATAGCTTTGGCCA CGG Site-specific mutation was introduced by the QuickChange method using GTATAGACCG (SEQ ID NO: 15) to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the E139P mutant. The pCold vector is a cold shock expression vector that utilizes the promoter of the cspA gene, one of the cold shock genes, and a translation enhancing element (TEE), His tag sequence, Factor Xa cleavage sequence, etc. are located downstream of the cspA promoter. Therefore, the expressed protein is expressed as a fusion protein containing the TEE sequence, His tag sequence, and Factor Xa cleavage sequence. In the present invention, no changes are made to the start codon (GTG) sequence of the wild-type enzyme gene derived from Bacillus megaterium. Therefore, the N-terminal amino acid of the enzyme protein site in the fusion protein is translated into valine. Subsequently, a transformant of E. coli BL21(DE3) was prepared using an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene.
[0054] Example 2 In this example, a mutant tetraprenyl-β-curcumene cyclase gene in which glutamine at position 325 was replaced with asparagine was constructed. The mutant tetraprenyl-β-curcumene cyclase gene was designed based on the gene sequence of tetraprenyl-β-curcumene cyclase (wild type) so that the 325th glutamine was replaced with asparagine, and was synthesized by optimizing the codons for the host E. coli. The synthesized gene was inserted into the cloning site (restriction enzyme NdeI / XhoI site) of the vector pColdI (Takara Bio Inc.), and using this vector gene as a template, the following primer was inserted so that the 257th tyrosine was replaced with alanine: Q325D forward primer: GCAGGTGTACCGCAG GAT GATCCCATGATTAAAG (SEQ ID NO: 16) and Q325D reverse primer: CTTTAATCATGGGATC ATC Site-specific mutations were introduced by the quick-change method using CTGCGGTACACCTGC (sequence number 17) to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the Q325D mutant. Subsequently, a transformant of E. coli BL21(DE3) was prepared using an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene.
[0055] Example 3 In this example, a mutant tetraprenyl-β-curcumene cyclase gene in which phenylalanine at position 530 was replaced with tryptophan was constructed. The mutant tetraprenyl-β-curcumene cyclase gene was designed based on the gene sequence of tetraprenyl-β-curcumene cyclase (wild type) so that phenylalanine at position 530 was replaced with tryptophan, and was synthesized by optimizing the codons for the host Escherichia coli. The synthesized gene was inserted into the cloning site (restriction enzyme NdeI / XhoI site) of the vector pColdI (Takara Bio Inc.), and using this vector gene as a template, the following primers were inserted into the cloning site (restriction enzyme NdeI / XhoI site) of the vector pColdI (Takara Bio Inc.) so that phenylalanine at position 530 was replaced with tryptophan: F530W forward primer: GGTGGA TGG GGAGAATCATGCTATAGC (SEQ ID NO: 18) and F530W reverse primer: CTCCCCAT CCA Site-specific mutations were introduced by the QuickChange method using CCGTCTTCTTGTTG (SEQ ID NO: 19) to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the F530W mutant. Subsequently, a transformant of E. coli BL21(DE3) was prepared using an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene.
[0056] Example 4 In this example, a mutant tetraprenyl-β-curcumene cyclase gene was constructed in which glutamic acid at position 139 was replaced with proline, glutamine at position 325 was replaced with asparagine, and phenylalanine at position 530 was replaced with tryptophan. Using the mutation introduction primers of Examples 1 to 3, site-specific mutations were similarly introduced by the quick change method to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the E139P / Q325D / F530W mutant. Subsequently, a transformant of E. coli BL21(DE3) was prepared using an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene.
[0057] 《Manufacturing method example 1》 In this example of the production method, the enzyme activity at 36° C. of the mutant tetraprenyl-β-curcumene cyclases obtained in Examples 1 to 4 was examined using squalene as a substrate. The transformants prepared in Examples 1 to 4 were each inoculated into LB medium (1 L) containing ampicillin (50 mg / L) and cultured with shaking at 37° C. for 3 hours. After the culture, 1 mM isopropyl-β-thiogalactopyranoside (IPTG) was added, and the culture was shaken at 15° C. for 24 hours to induce expression of the mutant tetraprenyl-β-curcumene cyclase. The cells were then collected by centrifugation (6,000×g, 10 min), washed with 50 mM Tris-HCl buffer (pH 7.5), and suspended in 15 mL of buffer A [50 mM Tris-HCl buffer (pH 7.5), 0.1 v / v% Tween 80, 0.1 w / v% sodium ascorbate, 2.5 mM dithiothreitol, 1 mM EDTA] per 5 g of cells, and sonicated (4°C, 20 min) using a UP2005 sonicator (Hielscher Ultrasonics, Teltow, Germany). The disrupted sample was centrifuged (12,300×g, 20 min) to obtain a crude enzyme solution. The crude extract was subjected to affinity purification of the target protein using the His tag. Purification was performed using a nickel column (Ni-NTA Agarose, QIAGEN) to prepare a recombinant enzyme solution (protein concentration: 100 μg / mL).
[0058] Squalene (100 μg) was mixed with Tween 80 (2 mg) to solubilize it, and then added to Buffer A (1 mL) to prepare a squalene solution. This squalene solution (0.5 mL) was added to the enzyme solution (0.5 mL) to prepare a reaction solution, which was then incubated at 30°C for 64 hours. In the reaction solution, the amount of enzyme protein was 50 μg, and the molar ratio (substrate / enzyme) of squalene (substrate) to mutant tetraprenyl-β-curcumene cyclase (enzyme) was approximately 170. After incubation, 15% potassium hydroxide-methanol (1.2 mL) was added to the reaction mixture to stop the enzyme reaction, and n-hexane (2.0 mL) was then added to the reaction mixture to extract the reaction product three times.
[0059] The content of the bicyclic compound (8α-hydroxypolypoda-13,17,21-triene) in the obtained extract (reaction composition) was measured by gas chromatography using the following apparatus and conditions. Equipment: Gas chromatograph "GC-2014" (Shimadzu), Integrator "Chromatopac CR-8A" (Shimadzu) Column: DB-1, capillary (length 30 m, ID 0.32 mm, film thickness 0.25 μm) (J&D) Injection temperature: 300℃ Column temperature: 220-300℃ (heating rate 3℃ / min) Column flow rate: 1.0 mL / min
[0060] The relative activity ratios of the reaction products (ambulin) in the resulting extracts (reaction compositions) are shown in FIG. 1(A).
[0061] The enzyme activity was also examined at reaction temperatures of 30° C., 33° C., and 36° C. As shown in FIG. 3 , the E139P mutant, Q325D mutant, F530W mutant, and E139P / Q325D / F530W mutant had superior enzyme activity at 36° C., compared to the wild-type tetraprenyl-β-curcumene cyclase.
[0062] Example 5 In this example, a mutant tetraprenyl-β-curcumene cyclase gene was constructed based on the Y167A / D373C mutant, in which glutamic acid at position 139 was replaced with proline. The procedure of Example 1 was repeated, except that the DNA of the Y167A / D373C mutant described in Patent Document 2 was used instead of the DNA of the wild-type tetraprenyl-β-curcumene cyclase of Bacillus megaterium, to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the Y167A / D373C / E139P mutant.
[0063] Example 6 In this example, a mutant tetraprenyl-β-curcumene cyclase gene was constructed based on the Y167A / D373C mutant, in which the 325th glutamine was replaced with asparagine. The procedure of Example 2 was repeated, except that the DNA of the Y167A / D373C mutant described in Patent Document 2 was used instead of the DNA of the wild-type tetraprenyl-β-curcumene cyclase of Bacillus megaterium, to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the Y167A / D373C / Q325D mutant.
[0064] Example 7 In this example, a mutant tetraprenyl-β-curcumene cyclase gene was constructed based on the Y167A / D373C mutant, in which phenylalanine at position 530 was replaced with tryptophan. The procedure of Example 3 was repeated, except that the DNA of the Y167A / D373C mutant described in Patent Document 2 was used instead of the DNA of the wild-type tetraprenyl-β-curcumene cyclase of Bacillus megaterium, to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the Y167A / D373C / F530W mutant.
[0065] Example 8 In this example, a mutant tetraprenyl-β-curcumene cyclase gene was constructed based on the Y167A / D373C mutant, in which glutamic acid at position 139 was replaced with proline, glutamine at position 325 was replaced with asparagine, and phenylalanine at position 530 was replaced with tryptophan. The procedure of Example 4 was repeated, except that the DNA of the Y167A / D373C mutant described in Patent Document 2 was used instead of the DNA of the wild-type tetraprenyl-β-curcumene cyclase of Bacillus megaterium, to obtain an expression vector containing the mutant tetraprenyl-β-curcumene cyclase gene of the Y167A / D373C / E139P / Q325D / F530W mutant.
[0066] 《Manufacturing method example 2》 In this example of the production method, the enzyme activity at 36° C. of the mutant tetraprenyl-β-curcumene cyclases obtained in Examples 5 to 8 was examined using squalene as a substrate. The enzyme activity was analyzed by repeating the procedure of Production Method Example 1. The content of ambrein in the obtained extract (reaction composition) was measured by gas chromatography using the apparatus and conditions of Production Method Example 1. The relative activity ratio of the reaction product (ambuline) in the obtained extract (reaction composition) is shown in Figure 2.
[0067] The enzyme activity was also examined at reaction temperatures of 30° C., 33° C., and 36° C. As shown in FIG. 3, the Y167A / D373C / E139P mutant, the Y167A / D373C / Q325D mutant, the Y167A / D373C / F530W mutant, and the Y167A / D373C / E139P / Q325D / F530W mutant had superior enzyme activity at 36° C., compared to the Y167A / D373C mutant. [Industrial Applicability]
[0068] The mutant tetraprenyl-β-curcumene cyclase of the present invention has improved thermostability and can efficiently produce bicyclic triterpene (8α-hydroxypolypoda-13,17,21-triene) and / or ambuline at high temperatures.
Claims
1. A mutant tetraprenyl-β-curcumene cyclase having one or more amino acids selected from the group consisting of: (a) tryptophan, which is the seventh amino acid residue in the QXXXGX(F / W) motif; (b) aspartic acid, which is the ninth amino acid residue from the C-terminus of the TALXSYA motif; and (c) proline, which is the fifth amino acid residue in the NGLYXWP motif, (i) The mutant tetraprenyl-β-curcumene cyclase has, based on the DXDD motif, a QXXXGX(W / F) motif at a position 100 or more amino acid residues away from the N-terminus, a NGLYXWP motif at a position 180 to 250 amino acid residues away from the N-terminus, an (A / S / G)RX(H / N)XXP motif at a position 180 to 250 amino acid residues away from the N-terminus, a (D / N)G(T / L)(L / F / Y)(Y / F)SY motif at a position 80 to 140 amino acid residues away from the N-terminus, and a (D / N)G(T / L)(L / F / Y)(Y / F)SY motif at a position 25 to 90 amino acid residues away from the N-terminus. a TALXSYA motif located 10-50 amino acid residues away from the N-terminus, a QXXX(G / A / S)X(F / W / Y) motif located 20-50 amino acid residues away from the C-terminus, a QXXXGX(F / W / Y) motif located 50-120 amino acid residues away from the C-terminus, a QXXXGXW motif located 120-170 amino acid residues away from the C-terminus, and the GXGX(G / A / P) motif located 180-250 amino acid residues away from the C-terminus, (ii) having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO:1; and (iii) exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate; Mutant tetraprenyl-β-curcumene cyclase.
2. The polypeptide constituting the mutant tetraprenyl-β-curcumene cyclase is (1) A polypeptide consisting of an amino acid sequence represented by SEQ ID NO:1, comprising the substitution of the phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the tryptophan described in (a), the substitution of the glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the aspartic acid described in (b), the substitution of the glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the proline described in (c), or a combination of two or more of these substitutions; (2) A polypeptide having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added in the amino acid sequence other than the substituted (a), (b), and / or (c) in the amino acid sequence represented by SEQ ID NO:1, including the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan as described above (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid as described above (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline as described above (c), or a combination of two or more thereof, and which uses squalene as a substrate and exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity. (3) A polypeptide having an amino acid sequence having 80% or more identity to an amino acid sequence other than the substituted amino acid sequences (a), (b), and / or (c), which includes the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline (c), or a combination of two or more of these substitutions, using squalene as a substrate; (4) A polypeptide comprising an amino acid sequence comprising the amino acid sequence represented by SEQ ID NO:1, the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of these substitutions, and which exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity using squalene as a substrate. (5) A polypeptide comprising an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added in an amino acid sequence other than the substituted (a), (b), and / or (c) in the amino acid sequence represented by SEQ ID NO: 1, including the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described above (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described above (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described above (c), or a combination of two or more thereof, and which uses squalene as a substrate and exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity; or (6) A polypeptide comprising an amino acid sequence having an identity of 80% or more to an amino acid sequence other than the substituted (a), (b), and / or (c) amino acid sequence, including a substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan (a), a substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid (b), a substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline (c), or a combination of two or more of these substitutions, in an amino acid sequence represented by SEQ ID NO:1, and which uses squalene as a substrate and exhibits 8α-hydroxypolypoda-13,17,21-triene-producing activity; The mutant tetraprenyl-β-curcumene cyclase according to claim 1,
3. The mutant tetraprenyl-β-curcumene cyclase according to claim 1, wherein the tryptophan in (a) is obtained by substituting an amino acid other than tryptophan with tryptophan, the aspartic acid in (b) is obtained by substituting an amino acid other than aspartic acid with aspartic acid, and the proline in (c) is obtained by substituting an amino acid other than proline with proline.
4. The mutant tetraprenyl-β-curcumene cyclase is (1) (d) the fourth amino acid residue of the DXDD motif is cysteine; (2) (d) the fourth amino acid residue of the DXDD motif is cysteine, and (e) the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif is alanine, (3) (d) the fourth amino acid residue of the DXDD motif is cysteine, and (f) the fourth amino acid residue of the GXGX (G / A / P) motif is alanine, or (4) (d) the fourth amino acid residue of the DXDD motif is cysteine, (e) the amino acid residue adjacent to the N-terminus of the (A / S / G)RX(H / N)XXP motif is alanine, and (f) the fourth amino acid residue of the GXGX(G / A / P) motif is alanine; and It exhibits ambrein-forming activity using squalene as a substrate. The mutant tetraprenyl-β-curcumene cyclase according to claim 1.
5. The polypeptide constituting the mutant tetraprenyl-β-curcumene cyclase contains a substitution of the aspartic acid at the 327th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with the cysteine of (d), (1) A polypeptide consisting of an amino acid sequence represented by SEQ ID NO:1, which includes the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan as described above (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid as described above (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline as described above (c), or a combination of two or more of the substitutions (a) to (c), and further includes the substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described above (e), the substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described above (f), or a combination of the substitutions (e) and (f). (2) In the amino acid sequence represented by SEQ ID NO:1, the amino acid sequence includes the substitution of phenylalanine at the 325th position from the N-terminus with tryptophan as described above in (a), the substitution of glutamine at the 325th position from the N-terminus with aspartic acid as described above in (b), the substitution of glutamic acid at the 139th position from the N-terminus with proline as described above in (c), or a combination of two or more of the substitutions (a) to (c), and in the amino acid sequence represented by SEQ ID NO:1, a polypeptide having an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted and / or added in an amino acid sequence other than the substituted (a), (b), (c), (d), (e) and / or (f) in the amino acid sequence represented by SEQ ID NO: 1, further comprising the substitution (e) of tyrosine at the 167th position from the N-terminus with alanine, the substitution (f) of leucine at the 596th position from the N-terminus with alanine, or a combination of substitutions (e) and (f); (3) A polypeptide comprising an amino acid sequence having an identity of 80% or more to an amino acid sequence other than the substituted (a), (b), (c), (d), (e), and / or (f), which comprises, in the amino acid sequence represented by SEQ ID NO: 1, the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described above, the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described above, the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described above, or a combination of two or more of the substitutions (a) to (c), and further comprising the substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above, the substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above, or a combination of substitutions (e) and (f); (4) A polypeptide comprising an amino acid sequence represented by SEQ ID NO:1, which includes the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with tryptophan as described above (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with aspartic acid as described above (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with proline as described above (c), or a combination of two or more of the substitutions (a) to (c), and further includes the substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described above (e), the substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO:1 with alanine as described above (f), or a combination of the substitutions (e) and (f), and which exhibits ambrein-producing activity using squalene as a substrate. (5) In the amino acid sequence represented by SEQ ID NO: 1, the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described above (a), the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described above (b), the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described above (c), or a combination of two or more of the substitutions (a) to (c), and or a polypeptide comprising an amino acid sequence in which one or several amino acids have been deleted, substituted, inserted, and / or added in an amino acid sequence other than the substituted (a), (b), (c), (d), (e), and / or (f) in the amino acid sequence represented by SEQ ID NO: 1, further comprising the substitution of tyrosine at the 167th position from the N-terminus with alanine as in (e), the substitution of leucine at the 596th position from the N-terminus with alanine as in (f), or a combination of substitutions (e) and (f); (6) A polypeptide comprising an amino acid sequence having an identity of 80% or more to an amino acid sequence other than the substituted (a), (b), (c), (d), (e) and / or (f) amino acid sequence, which includes, in the amino acid sequence represented by SEQ ID NO: 1, the substitution of phenylalanine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with tryptophan as described above, the substitution of glutamine at the 325th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with aspartic acid as described above, the substitution of glutamic acid at the 139th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with proline as described above, or a combination of two or more of the substitutions (a) to (c), and further including the substitution of tyrosine at the 167th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above, the substitution of leucine at the 596th position from the N-terminus in the amino acid sequence represented by SEQ ID NO: 1 with alanine as described above, or a combination of substitutions (e) and (f), and which exhibits ambrain-forming activity using squalene as a substrate; The mutant tetraprenyl-β-curcumene cyclase according to claim 4,
6. The mutant tetraprenyl-β-curcumene cyclase according to claim 4, wherein the tryptophan in (a) is substituted with an amino acid other than tryptophan by tryptophan, the aspartic acid in (b) is substituted with an amino acid other than aspartic acid by aspartic acid, the proline in (c) is substituted with an amino acid other than proline by proline, the cysteine in (d) is substituted with an amino acid other than cysteine by cysteine, the alanine in (e) is substituted with an amino acid other than alanine by alanine, and the alanine in (f) is substituted with an amino acid other than alanine by alanine.
7. A polynucleotide encoding the mutant tetraprenyl-β-curcumene cyclase according to any one of claims 1 to 6.
8. A microorganism comprising the polynucleotide of claim 7.
9. A vector comprising DNA having the polynucleotide of claim 7.
10. A transformant having the vector according to claim 9.
11. A method for producing 8α-hydroxypolypoda-13,17,21-triene, comprising reacting the mutant tetraprenyl-β-curcumene cyclase according to any one of claims 1 to 3 with squalene to obtain 8α-hydroxypolypoda-13,17,21-triene.
12. A method for producing ambrein, comprising reacting the mutant tetraprenyl-β-curcumene cyclase according to any one of claims 4 to 6 with squalene to obtain ambrein.
13. A method for producing ambrein, comprising culturing the microorganism according to claim 8.
14. A method for producing ambrein, comprising culturing the transformant according to claim 10.
Citation Information
Patent Citations
Variant type tetraprenyl-β-curcumene cyclase and method for producing ambrein
WO2017150695A1
Efficient method for producing ambrein
WO2019045058A1
Mutant tetraprenyl-β-curcumene cyclase and method for producing ambrein using same
WO2021193806A1
